Posted on:
Apr 3, 2016 01:32AM
- edited
Jan 20, 2017 01:20PM
by
JohnSmith
JohnSmith
wrote:
Jan 2017 UPDATE: Highlights from the first ever international ILC meeting will be discussed in a free webinar on: Monday, Jan. 30th, 2017 4-5pm EST.
To participate, please register here: https://attendee.gotowebinar.com/register/6547859304037292545
The First International ILC Symposium.
September 29-30, 2016 | Pittsburgh, Pennsylvania, USA
https://upci.upmc.edu/wcrc/ilcsymposium-info.cfm
The University of Pittsburgh Cancer Institute & Magee-Womens Research Institute will host the event.
Chair:
- Steffi Osterreich, PhD (University of Pittsburgh Cancer Institute)
She's the Principal Investigator of the Oesterreich Research Group, which consists of a collection of ILC researchers.
This group is responsible for the first ever US-based ILC Clinical Trial, "Endocrine Response of Lobular BC".
Co-Chairs:
- Nancy Davidson, MD (University of Pittsburgh Cancer Institute) She was the 2016 President of AACR at now at Fred Hutch in Seattle.
- Otto Metzger, MD (Harvard Medical School / Dana-Farber Cancer Institute in Boston)
Dr. Metzger was involved in the Breast International Group (BIG) 1-98 trial which compared the Letrozole (Femara) against Tamoxifen for postM ILC patients. His group launched the PELOPS Clinical Trial, which encourages ILC patient enrollment, and explores if adding Palbociclib (Ibrance) to hormone therapy improves outcome.
Patient Advocate: Heather Hillier
Oct 2016 UPDATE: The ILC Symposium was a success! This was a densely-packed scientific program with ~100 Oncology professionals. Ideas were shared and new collaborations were established.
30 survivors and co-survivors attended. An official ILC Advocacy group is being initiated.
This thread will remain active, since it serves as a template for the numerous unanswered questions that still need to be addressed. The research road that leads to new therapies can take a long time.
We encourage you to think about how we can advance the science and accelerate progress. If you have ideas, no matter how "outside of the box", please share.
A future ILC Symposium is slated for Fall 2018 in Boston, Massachusetts and we hope to see you there!
Wife was Age 45 at Dx 4/2014. BMX Surgery 6/2014 revealed: ILC, Stage 2 (Multifocal ILC, largest lesion 2.2 cm), Grade 2, ER+/PR+ (95%), HER2-, Ki-67 5-10%, Oncotype 11; Variant in the ATM gene
Dx
4/8/2014, ILC, Left, 2cm, Stage IIA, Grade 2, 0/3 nodes, ER+/PR+, HER2-,
Surgery
6/26/2014 Mastectomy; Reconstruction (left); Reconstruction (right)
Log in to post a reply